The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Additivity and the efficacy of immune checkpoint blockade-based combination regimens in urothelial cancer.
 
Noah Schlachter
Research Funding - Merck
 
Eric Miller
No Relationships to Disclose
 
Jonathan Anker
Patents, Royalties, Other Intellectual Property - Co-inventor on patent "IMMUNOSTIMULATORY BACTERIA FOR THE TREATMENT OF CANCER", Publication number 20190046588 (Inst)
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Adam Palmer
Honoraria - AstraZeneca; Kymera; Merck; Novartis
Consulting or Advisory Role - Merck; Sanofi
Research Funding - Merck
Travel, Accommodations, Expenses - Merck; Novartis